Navigation Links
Insulin may reduce several inflammatory factors induced by bacterial infection
Date:9/8/2010

BUFFALO, N.Y. -- Treating intensive care patients who develop life-threatening bacterial infections, or septicemia, with insulin potentially could reduce their chances of succumbing to the infection, if results of a new preliminary study can be replicated in a larger study.

A paper published online ahead of print in Diabetes Care reports that insulin lowered the amount of inflammation and oxidative stress in study participants who had been injected with a common bacteria, or endotoxin, known as LPS (lipopolysaccharide).

The study was conducted by University at Buffalo endocrinologists at Kaleida Health's Diabetes-Endocrinology Center of Western New York.

LPS, found in the outer membrane of various gram-negative bacteria, is known to increase the ability of the bacteria to cause hemorrhage, necrosis of the kidneys and shock, especially in immune-compromised patients.

The study involved 19 healthy subjects who were injected after an overnight fast with a dose of the endotoxin based on their weight. After the endotoxin injection, 10 participants were infused with insulin (plus dextrose to maintain normal glucose levels), and nine received saline to mimic the insulin infusion.

The infusions continued for six hours following the endotoxin injections. Participants then ate a 900 calorie meal and ate nothing else until the following morning.

Researchers monitored the subjects' temperature, pulse, blood pressure, headaches, body aches and chills for 24 hours following the endotoxin injection. Blood samples were collected one hour before the injection, at the time of injection and at one, two, four, six and 24 hours afterwards.

Monitoring showed that the endotoxin raised body temperature by three degrees -- from 98 to a peak of 101.3 at the four-hour mark, and produced body aches and headaches, which peaked between one and two hours. Results showed that insulin reduced the body-aches score but had no effect on temperature,

In addition, the endotoxin induced a rapid rise in several destructive and inflammatory factors, including reactive oxygen species (free radicals) and products of nitric oxide and fat metabolism. The insulin infusion led to total elimination of several pro-inflammatory factors and to a significant reduction in generation of reactive oxygen species and the products of fat metabolism.

Paresh Dandona, MD, PhD, UB distinguished professor of medicine and senior author on the study, says this study confirms the expectations arising out of the researchers' initial discovery of the anti-inflammatory effect of insulin.

"This study lays the foundation for further studies based on insulin infusion and the normalization of blood glucose concentrations in patients with endotoxemia and septicemia," says Dandona.

"Our endocrinology group demonstrated previously that insulin also has anti-inflammatory and cardioprotective effects in patients who had a heart attack, and we currently are conducting a study on the potential beneficial effects of insulin on acute stroke.

"Clearly, insulin may emerge with roles beyond those conceived when it was discovered in 1921 as a metabolic hormone, and has since been used for the treatment of diabetes to lower and control blood glucose concentrations," Dandona notes.


'/>"/>

Contact: Lois Baker
ljbaker@buffalo.edu
716-645-4606
University at Buffalo
Source:Eurekalert

Related biology news :

1. For insulin sensitive overweight patients, 1 session of exercise improves metabolic health
2. Decreasing insulin resistance prevents obesity-related cardiovascular damage
3. Findings show insulin -- not genes -- linked to obesity
4. Nanodiamonds deliver insulin for wound healing
5. Pitt study finds molecular link between insulin resistance and inflammation
6. Diabetes advance: Researchers find gene that causes resistance to insulin
7. CHEO RI study uses sophisticated genetic engineering to improve insulin-producing beta cells
8. New gene variants associated with glucose, insulin levels, some with diabetes risk
9. Scripps research scientists find new link between insulin and core body temperature
10. Structure of insulins docking point identified
11. Insulin-like signal needed to keep stem cells alive in adult brain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... -- Summary This report provides all the information ... and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ...
(Date:2/28/2017)... Feb. 28, 2017   Acuant , a leading ... announces significant enhancements to new and core technologies building ... products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity documents ... provides the fastest and most accurate capture software to ...
(Date:2/24/2017)... -- EyeLock LLC, a leader of iris-based identity authentication ... solution on the latest Qualcomm® Snapdragon™ 835 mobile ... Congress 2017 (February 27 – March 2, ... Stand 3E10. The Snapdragon 835 ... combination of hardware, software and biometrics technologies ...
Breaking Biology News(10 mins):
(Date:3/28/2017)... ... March 28, 2017 , ... T3D Therapeutics, ... new orally administered treatment for Alzheimer’s disease (AD), today announced that Dr. Kathleen ... we seek to uniquely treat the metabolic dysfunctions inherent in Alzheimer’s disease and ...
(Date:3/27/2017)... March 27, 2017 Roka Bioscience, Inc. (NASDAQ: ROKA), ... for the detection of foodborne pathogens,  today announced that ... Company Spring 2017 Convention on March 29 at 9:50am ET. ... Marquis. About Roka Bioscience ... Roka Bioscience is ...
(Date:3/27/2017)... ATLANTA , March 27, 2017 Cousins Properties ... of the world,s leading biotechnology companies, has signed a 10-year, ... foot Class A office asset located in the Westshore submarket ... "We are thrilled that Amgen has chosen Corporate Center for ... Larry Gellerstedt , president and chief executive officer of ...
(Date:3/27/2017)... Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), ... the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 is ... ) and the US National Institutes of Health. ... ... ...
Breaking Biology Technology: